Skip to main content

Laparoscopic bariatric surgery in England

A study by Elaine Burns and colleagues published in the BMJ describes the large increase in NHS laparoscopic bariatric surgery operations observed in recent years, with an increase from 238 operations in 2000 to 2543 in 2007. Recent years have also seen large increases in NHS prescribing and spending on drugs for obesity. For example, a study published in the Journal of Public Health Medicine reported that between 1998 and 2005, Orlistat prescriptions in England rose 36-fold from 17,880 to 646,700 and their total cost increased by over 35-fold to £27 million. Sibutramine prescriptions rose from 53,393 in 2001 to around 227,000 in 2005, a 4-fold increase, at a cost of £11 million in 2005.Despite this increased spending on medical and surgical NHS interventions, rates of obesity continue to increase inexorably and around 25% of adults in England are now considered to be obese, with a BMI of 30 or greater.The failure of medical treatments for obesity is further illustrated by the subsequent withdrawal of Rimonabant and Sibutramine because of concerns about their safety. Although medical and surgical treatments have an important role in the management of obesity, particularly in some high risk groups, the key to tackling obesity lies in wider societal approaches, involving joint working between the NHS, local and national government, and the private sector.  

Comments

Popular posts from this blog

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...

What makes a good doctor – and who gets to decide?

What Makes a Good Doctor? This is the question that Waseem Jerjes and I explore in the Journal of the Royal Society of Medicine . It is a key question that underpins the architecture of medical education, clinical practice, regulation, and professional identity. It cannot be answered by regulators, educators, or employers in isolation. It must be answered together – by doctors and patients – revisited throughout a career, and adapted as society and the profession change. Without that shared reflection, the danger is not simply disillusionment, but the erosion of the moral foundations of clinical work. As we enter an era when diagnosis will increasingly involve artificial intelligence and when performance metrics reward volume over value, reclaiming this question as a professional one is imperative. The integrity of our institutions – and of the practitioners within them – depends on reimagining excellence in inclusive, relational terms. A good doctor is not a flawless technician or a f...